Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
Funcin cognitiva: Puede mejorar la memoria y la concentracin
FOR SOME URIs MAY PROGRESS TO MORE SEVERE CONDITIONS SOURCE: Centers for Disease Control and Prevention
Individuals with a history of allergies to other medications, particularly other GLP-1 receptor agonists such as liraglutide (Victoza) or dulaglutide (Trulicity), may be at increased risk and should discuss this history with their prescribing clinician before starting Ozempic
Glossmann HH, Lutz O
Today, Meta is investing in what the next decade of compounding will require: expanded operational leadership, deeper compliance infrastructure, and a second Las Vegas facility opening Q3 2026 purpose-built to run at standard from day one